Searle Secures DRAP Approval to Launch Denosumab Injections in Pakistan

The Searle Company Limited (SEARL) has received approval from the Drug Regulatory Authority of Pakistan (DRAP) to market and sell Denosumab injections, a biosimilar drug used in the treatment of osteoporosis and oncology care. This marks a significant expansion in the company’s pharmaceutical portfolio. In a notice to the Pakistan Stock Exchange (PSX) on Monday, SEARL announced the successful registration of Denosumab injections in 120mg and 60mg dosages. The company has been granted rights under a license agreement with Mabwell Pharmaceuticals, China, the manufacturer of the drug, to market and sell the biosimilar in Pakistan. Denosumab, a monoclonal antibody, is used for managing osteoporosis (60mg) and oncology care (120mg). SEARL shared that it is now preparing for the commercial launch of the injections in Pakistan, calling it a “significant milestone” in its efforts to expand its product offerings. “This development reflects the company’s commitment to enhancing its product portfolio, strengthening its business, and improving the quality of its earnings, thereby creating greater value for shareholders,” the company stated. SEARL, incorporated in Pakistan in 1965 as a private limited company and later converted into a public limited company, is a subsidiary of International Brands (Private) Limited. Its principal activities include the manufacturing and sale of pharmaceutical, consumer health, and nutritional products.